加载中
NASDAQHealthcareBiotechnology
最新数据
US$20.71
−US$0.54 · -2.54%
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
常规交易时段
US$20.71
−US$0.54 · -2.54%
盘中时间采用ET。市场数据可能有所延迟。
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
日内区间
当前US$20.71
52周区间
当前US$20.71
盘中时间采用ET。市场数据可能有所延迟。
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
日内区间
当前US$20.71
52周区间
当前US$20.71
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2250.3万 USD | 4556.3万 USD | 1409万 USD | 1.03亿 USD | — |
| 销货成本 | 5.9万 USD | — | — | — | — |
| 毛利 | 2244.4万 USD | 4556.3万 USD | 1409万 USD | 1.03亿 USD | — |
| 研究与开发 | 1.42亿 USD | 1.51亿 USD | 1.59亿 USD | 8674.4万 USD | 2897.4万 USD |
| 销售、一般及管理费用 | 1.06亿 USD | 7044.6万 USD | 3763.3万 USD | 1950.7万 USD | 567.7万 USD |
| 营业费用 | 2.48亿 USD | 2.22亿 USD | 1.97亿 USD | 1.06亿 USD | 3497.7万 USD |
| 利息收入 | 2759.2万 USD | 1688.1万 USD | 1022.01万 USD | — | — |
| 利息支出 | — | — | 679.91万 USD | 28.7万 USD | 41.1万 USD |
| 折旧和摊销 | 22万 USD | 11.3万 USD | 4.9万 USD | 9000 USD | 5000 USD |
| 营业利润 | −2.26亿 USD | −1.76亿 USD | −1.83亿 USD | −355.7万 USD | −3497.7万 USD |
| 净利润 | −2.04亿 USD | −2.42亿 USD | −1.77亿 USD | −2263.4万 USD | −4178.5万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$51.33
上涨空间 147.85%价格历史记录不可用
最高：US$58.00平均的：US$51.33最低：US$45.00报告持有此股票敞口的交易所交易基金。
Capital Group U.S. Small and Mid Cap ETFCGMM1637.15万0.46%35.54亿 USD0.51%US$31.245-0.78%
iShares Biotechnology ETFIBB1280.35万0.12%108.2亿 USD0.44%US$201.16-1.52%
Vanguard Health Care ETFVHT497.72万0.02%220亿 USD0.09%US$316.92-1.17%
ALPS Medical Breakthroughs ETFSBIO322.67万1.73%1.87亿 USD0.50%US$52.47-2.56%
Fidelity Fundamental Small-Mid Cap ETFFFSM130.63万0.08%14.4亿 USD0.43%US$33.79-0.68%
iShares ESG Aware MSCI USA Small-Cap ETFESML107.47万0.04%27.28亿 USD0.17%US$52.215-0.47%
Fidelity Nasdaq Composite Index ETFONEQ74.73万0.01%109.4亿 USD0.21%US$107.14-0.20%
Fidelity MSCI Health Care Index ETFFHLC70.18万0.02%35.4亿 USD0.08%US$81.88-1.17%Capital Group U.S. Small and Mid Cap ETFCGMMiShares Biotechnology ETFIBBVanguard Health Care ETFVHTALPS Medical Breakthroughs ETFSBIOFidelity Fundamental Small-Mid Cap ETFFFSMiShares ESG Aware MSCI USA Small-Cap ETFESMLFidelity Nasdaq Composite Index ETFONEQFidelity MSCI Health Care Index ETFFHLCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
